Enfusion Results Presentation Deck

Strong growth trends with expanding profitability $ in millions $31.9 4Q21 4Q21 40.6% *:enfusion $34.1 Revenue $36.5 $39.2 1Q22 2Q22 3Q22 YOY Growth $40.5 4Q22 1Q22 2Q22 3Q22 4Q22 40.2% 38.2% 34.8% 27.2% $22.1 $21.7 4Q21 Gross Profit and (1) Adjusted Gross Profit $23.5 $23.2 4Q21 $26.0 $25.7 Adjusted Gross Profit $27.6 $27.2 1Q22 2Q22 3Q22 4Q22 -Gross Profit Gross Margin and Adjusted Gross Margin 1Q22 2Q22 3Q22 Gross Margin 68.1% 67.8% 70.3% 69.4% Adjusted Gross Margin 69.3% 68.9% 71.2% 70.5% $27.5 See appendix for non-GAAP reconciliations. (1) $27.2 4Q22 67.2% 68.0% $3.2 4Q21 Net Income and Adjusted EBITDA $(293.9) $(12.5) 4Q21 NM $1.8 (1) $5.3 $5.4 $2.6 $(4.1) 1Q22 2Q22 3Q22 4Q22 Adjusted EBITDA -Net Income Net Income Margin and Adjusted EBITDA Margin 1Q22 2Q22 3Q22 Net Income Margin NM NM 6.6% $6.8 Adjusted EBITDA Margin 10.0% 5.4% 14.5% 13.9% $0.8 4Q22 1.9% 16.7% ($3.1) ($5.8) 4Q21 4Q21 NM Operating Cash Flow and Adjusted Free Cash Flow (1) NM PROPRIETARY AND CONFIDENTIAL ($4.1) $2.9 ($1.4) $7.8 $4.8 Operating Cash Flow Margin and Adjusted Free Cash Flow Conversion ($9.4) 1Q22 2Q22 3Q22 4Q22 Adjusted FCF -Operating CF 1Q22 2Q22 3Q22 Operating Cash Flow Margin NM 7.9% 20.0% $7.5 Free Cash Flow Conversion NM NM 87.6% $3.6 Ⓒ2023 ENFUSION. ALL RIGHTS RESERVED. 4Q22 18.6% 53.4% 11

View entire presentation